MedTrace Logo

Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients

NCT00812032 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-05-27

No results posted yet for this study

Summary

The efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes. The aim of the investigators study is to test the laboratory response to different dosing of aspirin in type 2 Diabetes Mellitus. The investigators will compare the regular dose of 75mg once daily to 75 mg twice daily or to 320 mg once daily. The hypothesis of the study is that twice daily dosing of aspirin may improve the response to aspirin.

Conditions

Interventions

DRUG

Aspirin

75 mg per day versus 75 mg twice daily and 320mg once daily

DRUG

aspirin

crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.

Sponsors & Collaborators

Principal Investigators

  • Paul Hjemdahl, MD, PhD · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812032 on ClinicalTrials.gov